中国临床新医学
中國臨床新醫學
중국림상신의학
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
2014年
10期
953-956
,共4页
肺炎支原体肺炎%阿奇霉素%痰热清注射液%联合用药
肺炎支原體肺炎%阿奇黴素%痰熱清註射液%聯閤用藥
폐염지원체폐염%아기매소%담열청주사액%연합용약
Mycoplasma pneumoniae pneumonia(MPP)%Azithromycin%Tanreqing injection%Drug combination
目的:观察阿奇霉素联合痰热清注射液治疗小儿肺炎支原体肺炎( MPP )的效果。方法将MPP患儿100例随机分为观察组和对照组各50例,观察组采用阿奇霉素联合痰热清注射液治疗,对照组单用阿奇霉素治疗。比较两组的疗效。结果观察组治疗后体温恢复正常时间、咳嗽症状消失时间、肺部体征消失时间、X线胸片吸收好转时间、总病程等方面较对照组明显缩短,差异有统计学意义( P<0.01);观察组疗效优于对照组,差异有统计学意义(P<0.01);观察组无复发,对照组复发4例(8.0%)。结论阿奇霉素联合痰热清注射液治疗小儿MPP疗程短、治愈率高、复发率低,值得临床上推广应用。
目的:觀察阿奇黴素聯閤痰熱清註射液治療小兒肺炎支原體肺炎( MPP )的效果。方法將MPP患兒100例隨機分為觀察組和對照組各50例,觀察組採用阿奇黴素聯閤痰熱清註射液治療,對照組單用阿奇黴素治療。比較兩組的療效。結果觀察組治療後體溫恢複正常時間、咳嗽癥狀消失時間、肺部體徵消失時間、X線胸片吸收好轉時間、總病程等方麵較對照組明顯縮短,差異有統計學意義( P<0.01);觀察組療效優于對照組,差異有統計學意義(P<0.01);觀察組無複髮,對照組複髮4例(8.0%)。結論阿奇黴素聯閤痰熱清註射液治療小兒MPP療程短、治愈率高、複髮率低,值得臨床上推廣應用。
목적:관찰아기매소연합담열청주사액치료소인폐염지원체폐염( MPP )적효과。방법장MPP환인100례수궤분위관찰조화대조조각50례,관찰조채용아기매소연합담열청주사액치료,대조조단용아기매소치료。비교량조적료효。결과관찰조치료후체온회복정상시간、해수증상소실시간、폐부체정소실시간、X선흉편흡수호전시간、총병정등방면교대조조명현축단,차이유통계학의의( P<0.01);관찰조료효우우대조조,차이유통계학의의(P<0.01);관찰조무복발,대조조복발4례(8.0%)。결론아기매소연합담열청주사액치료소인MPP료정단、치유솔고、복발솔저,치득림상상추엄응용。
Objective To investigate the therapeutic efficacy of azithromycin combined with Tanreqing injec-tion in treatment of children with mycoplasma pneumoniae pneumonia( MPP) .Methods One hundred children with MPP were randomly divided into two groups with 50 cases in each group, the observation group received the therapy of azithromycin combined with Tanreqing injection, while the control group received the therapy of azithromycin only, and then comparison was made between the two groups in clinical effects.Results There was a significant difference between the two groups in the time of the disappearance of fever,cough and pulmonary signs and X-ray recovery( P<0.01), and there was also a statistic difference in curative rate(P<0.01).No case relapsed in the observation group while 4 cases(8.0%) in the control group.Conclusion The therapy of azithromycin combined with Tanreqing injec-tion has obvious superiority with shorter courses, higher curative rate and lower relapse rate than single azithromycin in treatment of children with MPP, worthy of clinical popularization and application.